"Positive skin biopsy for p-α-syn occurs across the spectrum of cognitive presentations of Lewy body disease including prodromal DLB, albeit at a lower frequency in this retrospective review of atypical cases compared with typical clinical presentations" https://t.co/z9hsNtCfwf

Very useful review of the small-molecule therapeutics field for GBA1-associated #Parkinsons; "Clinical trials of GBA1-modulating therapeutics will be challenging with regard to the optimal timing of the intervention & appropriate outcome parameters" https://t.co/oSOIWAV9A7

We need more programmes like Psicológica - per review published with open access in DIGITAL.CSIC, the institutional repository of the Spanish National Research Council. The publication costs are ~$30 per study: https://t.co/ujYd8eNsnp

And this part is pretty gangster: “If publishers believe our estimates are not accurate, we would appreciate it if they would publish their data & be transparent. Their lack of transparency is precisely what has made our work so slow & difficult" Hear, hear!

"“This means that for every $1,000 that the academic community spends on publishing in Elsevier, about $400 go into the pockets of its shareholders” And the peer reviewers get nothing...

"This system, known as “publish or perish,” has given rise to a huge business with perverse incentives to produce more & more insubstantial studies; publishers earn more money, & researchers pad their resumes with little to no effort" I like the phrase “research vampirization”

Disturbing reading: "Using mainly public funds, the scientific community paid the 5 large publishers $1.06 billion in 4 years. And according to this estimate, the sum covers only the fees to publish open access studies" https://t.co/s3X3HfxJ6b

New clinical trial registered: PREVENTION-IN-PD - The development of a multidomain lifestyle intervention study for 99 people with prodromal & clinical #Parkinsons in Germany; Support in 4 areas: exercise, Mediterranean diet, sleep, & cognitive training https://t.co/LDV8Te1gD7

New clinical trial registered: Annovis Bio @AnnovisBio initiate an open-label Phase 2/3,36 month clinical trial investigating the long-term safety of Buntanetap in treating 500 participants with #Parkinsons https://t.co/KKxU7S7dmp

New clinical trial registered: @narayananlab & collaborators initiate the Terazosin And Metabolic Engagement in Parkinson's Disease (or TAME-PD) study - a Phase 1/2 study assessing 26 weeks of terazosin in 100 people with early #Parkinsons https://t.co/oS70o9dTFM

New review from @touteiro & co highlights new research on alpha synuclein–lipid interactions across different experimental models & proposes that early disruptions in neuronal lipid metabolism may lead to altered membrane composition & aggregation of aSyn https://t.co/cu7xDft6RH

New research from @AlisonYarnall & @Mobilise_D colleagues reports that distinct digital mobility outcomes patterns across #Parkinsons severity & between PD & controls support their utility as sensitive, scalable outcome measures for future clinical trials https://t.co/yQvrelg0qu

Researchers present a novel cell-penetrating PEP-1-Phosphoglycerate mutase 5 (PGAM5) fusion protein that rescues models of #Parkinsons https://t.co/LRCv1rU0gP

A prospective, blinded study evaluating phosphorylated alpha-synuclein detection from skin biopsies finds 96.0% (48/50) positive results in dementia with Lewy bodies cases, 31% (8/26) of controls with⬇️MoCA, & 3.3% (4/120) of controls with normal MoCA. https://t.co/fvwPcO4rck

Walter Koroshetz, director of the National Institute of Neurological Disorders & Stroke, emailed NINDS staff late Friday night explaining that a request to reappoint him was denied, adding that his current temporary extension ends Sunday https://t.co/UVqQKOUpsM

Researchers report that "dopamine caused α-synuclein oligomerization via oxidation of methionine residues" can be inhibited by Pyridoxamine (a form of vitamin B6) in a dose-dependent manner, through stable adduct formation (scavenging dopamine o-quinone) https://t.co/O8MezU1eLk

New research finds that #Parkinsons-associated alpha-synuclein amyloids can degrade adenosine triphosphate (ATP) in a catalytic fashion (producing adenosine diphosphate & adenosine monophosphate); Upon prolonged incubation, all ATP is irreversibly consumed https://t.co/NCkDBmltI5

Non-invasive brain stimulation is stepping up to be part of the future of neurology. Non-invasive brain stimulation refers to techniques that gently change brain activity from outside the head without surgery. Rektorová and colleagues describe in a new paper in Nature Reviews

New review explores the historical developments & key milestones in ubiquitination research, with a focus on its roles in both health & disease (#Parkinsons gets a mention); Fascinating evolution of potential therapeutic approaches https://t.co/MK7KvZpGXZ

By analysing the membrane proteome for α-syn fibril binding, researchers propose that a cell surface mGluR4–NPDC1 complex participates in the neurodegeneration induced by #Parkinsons-associated alpha synuclein; Transgenic KO mice = protection https://t.co/UPyxUpmK1V